Based on our findings, we propose that the bioactivity of WIB is mediated through AMPK activation, which modulates adipose tissue formation and liver metabolism, ultimately contributing to the inhibition of lipogenesis and anti-obesity effects [66,67]. Here, PRKAA1 is linked to obesity disorder.